Arranon (Nelarabine) for Leukemia

Overview
Arranon is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat T-cell acute lymphoblastic leukemia (ALL) and T-cell lymphoblastic lymphoma (T-LBL). Arranon is indicated in cases where cancer has relapsed or failed to respond after at least two previous drug regimens. Arranon may also be referred to by its drug name, nelarabine.

Arranon is an anticancer drug. Arranon is a member of a class of drugs called antimetabolites. Arranon is believed to work by interfering with the DNA synthesis in replicating cells.

How do I take it?
Arranon is administered by intravenous infusion on specific days of a 21-day cycle.

Arranon comes in the form of a single-dose vial.

Side effects
The FDA-approved label for Arranon lists common side effects including headache, fever, fatigue, dizziness, sleepiness, cough, trouble breathing, nausea, vomiting, diarrhea, constipation, sensations of numbness, prickling, or tingling, and low blood cell counts.

Rare but serious side effects listed for Arranon include severe neurological deficits such as seizures, altered mental state, paralysis, and muscle weakness that can be permanent. Arranon can also cause fetal harm in pregnant women.

For more details about this treatment, visit:

Nelarabine — Leukemia and Lymphoma Society
https://www.lls.org/drug/nelarabine